Hpv Vaccine Knowledge and Hesitancy among Healthcare Workers in Anambra State

Human papillomavirus (HPV) vaccination remains a cornerstone of cervical cancer prevention and the control of other HPV-related malignancies. Healthcare workers are critical to the success of vaccination programmes, as their knowledge, attitudes, and recommendations strongly influence public acceptance. This study assessed the level of knowledge, willingness, and factors influencing hesitancy toward HPV vaccination among healthcare workers in Anambra State, Nigeria. A cross-sectional study was conducted among 430 healthcare workers selected using a multistage stratified random sampling technique across public and private health facilities. Data were collected using a structured, self-administered questionnaire and analysed with IBM SPSS version 26. Descriptive statistics were used to summarise key variables, while inferential analyses—including chi-square tests, independent t-tests, analysis of variance, and correlation analysis—were employed to examine associations between knowledge, willingness, and selected sociodemographic characteristics. Statistical significance was set at p < 0.05. Overall, knowledge of HPV and its vaccine was high, with 91.6% of respondents demonstrating adequate knowledge. Awareness of the association between HPV and cervical cancer was high; however, knowledge that HPV affects both males and females was comparatively lower. Willingness to accept and recommend HPV vaccination was also high, with 81.4% of respondents exhibiting high willingness. Vaccine safety concerns and fears of long-term side effects were the most commonly reported factors influencing hesitancy. Knowledge scores differed significantly by age, profession, and practice location, while willingness varied by marital status, religion, level of healthcare, and practice location. A weak but statistically significant positive correlation was observed between knowledge and willingness to accept HPV vaccination (r = 0.152, p = 0.002). In conclusion, healthcare workers in Anambra State demonstrated high levels of knowledge and strong willingness to support HPV vaccination, despite residual concerns and misconceptions. Strengthening targeted continuing professional education, ensuring sustained institutional support, and improving vaccine availability may further enhance healthcare worker advocacy and HPV vaccine uptake.

Human papillomavirus; HPV vaccine; vaccine hesitancy; healthcare workers

1. Garland SM. Human papillomavirus update with a particular focus on cervical disease. Pathology. 2009;41(3):213–24. [Google Scholar] [Crossref]

2. Chidebe A, Osayi L, Torode J. Global disparities in HPV-related cancers: implications for low- and middle-income countries. Int J Public Health. 2025;70:160–8. [Google Scholar] [Crossref]

3. Milano G, Russo M, De Luca F, et al. Human papillomavirus: molecular biology, oncogenesis and prevention. Viruses. 2023;15(4):912. [Google Scholar] [Crossref]

4. Kutz K, Bauer HM, Franco EL. Oncogenic human papillomavirus genotypes and cancer risk. Lancet Oncol. 2023;24(2):e65–73. [Google Scholar] [Crossref]

5. World Health Organisation. Cervical cancer fact sheet. Geneva: WHO; 2024. [Google Scholar] [Crossref]

6. Kombe Kombe AJ, Li B, Zahid A, et al. Epidemiology and burden of HPV-related cancers. Front Oncol. 2021;11:671–9. [Google Scholar] [Crossref]

7. Milano G, Russo M, De Luca F, et al. Global cancer burden attributable to HPV. Viruses. 2023;15(4):912. [Google Scholar] [Crossref]

8. Anoruo JI, Ezechi OC, Musa J, et al. Prevalence and genotype distribution of HPV infection in Nigeria. BMC Infect Dis. 2022;22:214. [Google Scholar] [Crossref]

9. Tesfaye A, Getachew S, Desta M. Global prevalence of human papillomavirus infection: a systematic review. J Glob Health. 2024;14:04012. [Google Scholar] [Crossref]

10. ICO/IARC Information Centre on HPV and Cancer. Nigeria: human papillomavirus and related cancers. Lyon: IARC; 2023. [Google Scholar] [Crossref]

11. Lawal AT, Adebayo SB, Ogunbiyi OJ. Cervical cancer burden in Nigeria: current trends and future projections. Niger J Clin Pract. 2023;26(9):1183–90. [Google Scholar] [Crossref]

12. McDowell M. The WHO cervical cancer elimination strategy: progress and challenges. Lancet Glob Health. 2024;12(1):e14–6. [Google Scholar] [Crossref]

13. Okeke M.C. Nigeria introduces HPV vaccine into routine immunisation. Abuja: NHW; 2024. [Google Scholar] [Crossref]

14. Okolie EA, Nwadike BI. Policy perspectives on HPV vaccine rollout in Nigeria. Health Policy Afr. 2023;6(2):55–62. [Google Scholar] [Crossref]

15. Njogu J, Wamai RG, Kariuki S, et al. Healthcare provider recommendation and vaccine acceptance. Vaccine. 2024;42(5):782–9. [Google Scholar] [Crossref]

16. Balogun MR, Omotade OO. Vaccine hesitancy among healthcare workers in Nigeria. Hum Vaccin Immunother. 2022;18(1):1–8. [Google Scholar] [Crossref]

17. Bakare O, Akinwale OP, Adebowale AS. Knowledge and attitudes of healthcare workers toward HPV vaccination in Nigeria. BMC Public Health. 2024;24:389. [Google Scholar] [Crossref]

18. de Araújo TM, Souza FM, Leite Á. Vaccine hesitancy among health professionals: a global concern. Public Health. 2022;205:26–33. [Google Scholar] [Crossref]

19. Lin C, Tu P, Beitsch LM. Confidence and hesitancy among healthcare workers toward vaccines. Vaccine. 2021;39(37):5424–31. [Google Scholar] [Crossref]

20. Paterson P, Meurice F, Stanberry LR. Vaccine hesitancy and healthcare providers. Vaccine. 2016;34(52):6700–6. [Google Scholar] [Crossref]

21. LaMontagne DS, Bloem P, Brotherton JML. Progress in HPV vaccination. Vaccine. 2017;35(37):4627–32. [Google Scholar] [Crossref]

22. Sankaranarayanan R, Prabhu PR, Pawlita M. Primary prevention of cervical cancer through HPV vaccination. Int J Gynaecol Obstet. 2013;123(2):97–102. [Google Scholar] [Crossref]

23. Black E, Richmond R. Prevention of cervical cancer in sub-Saharan Africa. Int J Womens Health. 2018;10:119–32. [Google Scholar] [Crossref]

24. Setia MS. Methodology series module 3: cross-sectional studies. Indian J Dermatol. 2016;61(3):261–4. [Google Scholar] [Crossref]

25. Anambra State Ministry of Health. Health facilities directory. Awka: ASMOH; 2023. [Google Scholar] [Crossref]

26. National Primary Health Care Development Agency. Nigeria health facility registry. Abuja: NPHCDA; 2022. [Google Scholar] [Crossref]

27. Federal Ministry of Health. National health system profile: Nigeria. Abuja: FMOH; 2021. [Google Scholar] [Crossref]

28. Cochran WG. Sampling techniques. 3rd ed. New York: John Wiley & Sons; 1977. [Google Scholar] [Crossref]

29. University of Central Arkansas. Sampling techniques and procedures in research. Conway: UCA; 2013. [Google Scholar] [Crossref]

30. Bakare O, Akinwale OP, Adebowale AS. Knowledge and attitudes of healthcare workers toward HPV vaccination in Nigeria. BMC Public Health. 2024;24:389. [Google Scholar] [Crossref]

31. Souza FM, Leite Á. Vaccine hesitancy among health professionals: A case study of West African. Public Health. 2024;21:26–13. [Google Scholar] [Crossref]

32. Lin C, Tu P, Beitsch LM. Confidence and hesitancy among healthcare workers toward vaccines. Vaccine. 2021;39(37):5424–31. [Google Scholar] [Crossref]

33. Paterson P, Meurice F, Stanberry LR, et al. Vaccine hesitancy and healthcare providers. Vaccine. 2016;34(52):6700–6. [Google Scholar] [Crossref]

34. World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: WHO; 2020. [Google Scholar] [Crossref]

35. Bruni L, Albero G, Serrano B, et al. Human papillomavirus and related diseases worldwide. Lancet Glob Health. 2021;9(2):e191–203. [Google Scholar] [Crossref]

36. Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020;40(5):602–8. [Google Scholar] [Crossref]

37. Bakare O, Akinwale OP, Adebowale AS. Knowledge and attitudes of healthcare workers toward HPV vaccination in Nigeria. BMC Public Health. 2024;24:389. [Google Scholar] [Crossref]

38. Lin C, Tu P, Beitsch LM. Confidence and hesitancy among healthcare workers toward vaccines. Vaccine. 2021;39(37):5424–31. [Google Scholar] [Crossref]

39. Leite Á, Okeke M. Vaccine hesitancy in Nigeria. Public Health. 2019;5:26–43. [Google Scholar] [Crossref]

40. Holman DM, Benard V, Roland KB. Barriers to HPV vaccination. Prev Med. 2014;69:1–7. [Google Scholar] [Crossref]

41. Nguyen-Huu NH, Thilly N, Derrough T, et al. HPV vaccination coverage and knowledge gaps. Vaccine. 2020;38(5):1073–82. [Google Scholar] [Crossref]

42. Paterson P, Meurice F, Stanberry LR. Vaccine hesitancy and healthcare providers. Vaccine. 2016;34(52):6700–6. [Google Scholar] [Crossref]

43. Dubé E, Gagnon D, MacDonald NE. Strategies to address vaccine hesitancy. Hum Vaccin Immunother. 2015;11(8):1989–99. [Google Scholar] [Crossref]

44. Adejumo OA, Olatunji AO, Adegboye OA. HPV vaccine acceptance in Nigeria. Afr J Reprod Health. 2021;25(3):44–55. [Google Scholar] [Crossref]

45. Donahue KL, Stupiansky NW, Alexander AB. Acceptability of HPV vaccination. J Adolesc Health. 2015;56(4):402–8. [Google Scholar] [Crossref]

46. Betsch C, Schmid P, Heinemeier D. Beyond confidence: vaccine decision-making. PLoS One. 2018;13(12):e0208601. [Google Scholar] [Crossref]

47. Larson HJ, Clarke RM, Jarrett C. Measuring vaccine hesitancy. Vaccine. 2015;33(34):4161–9. [Google Scholar] [Crossref]

48. MacDonald NE. Vaccine hesitancy: definition and determinants. Vaccine. 2015;33(34):4161–4. [Google Scholar] [Crossref]

49. Ozawa S, Stack ML. Public trust and vaccination. Vaccine. 2013;31(37):4107–12. [Google Scholar] [Crossref]

50. Thomson A, Robinson K, Vallée-Tourangeau G. Vaccine hesitancy. BMJ. 2016;352:i120. [Google Scholar] [Crossref]

51. WHO SAGE Working Group. Report on vaccine hesitancy. Geneva: WHO; 2014. [Google Scholar] [Crossref]

52. Brewer NT, Chapman GB, Rothman AJ. Increasing vaccination. Psychol Sci Public Interest. 2017;18(3):149–207. [Google Scholar] [Crossref]

53. Dubé E, Laberge C, Guay M. Vaccine hesitancy. Hum Vaccin Immunother. 2013;9(8):1763–73. [Google Scholar] [Crossref]

• Treasure of 6th Edition of Organon of Medicine- Lm Potency
• Neurobehavioral and Immune-Histochemical Effects of Daucus Carota Ethanolic Leaf Extract in Cadmium-Induced Toxicity of the Hippocampus and Prefrontal Cortex of Adult Wistar Rats
• Unveiling the Antimicrobial Potential of Homoeopathic Sarcode and Bowel Nosode: A Study on Histaminum and Dysenteriae Co against Escherichia Coli And Klebsiella Bacteria
• Incidence of Cardiovascular Events in Patients Receiving Hematopoietic Stem Cell Transplant (HSCT) in HCTM – (A Retrospective Cohort Study)
• A Prospective Case Study Examining the Effectiveness of Homoeopathic Medicine in Treating Degenerative Changes in the Lumbar Spine-A Case Report